IMRT for carcinomas of the oropharynx and oral cavity

Rupert K. Schmidt-Ullrich, David Buck, Nesrin Dogan, Jeffrey Siebers, Monica Morris, Yan Wu

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Despite significant progress over the past decade, the loco-regional control and survival rates of 50-60% for patients with locally-advanced oropharyngeal (OP) head and neck squamous cell carcinomas (HNSCC) with radiotherapy (RT) alone leave room for improvement [21] considering the limited options for salvage treatment after failure of the initial therapy. Current standards of RT have been re-defined by the RTOG- 9003 trial, comparing standard fractionation (SF) of 70 Gy, delivered in 35 fractions over 47 treatment days, with three different altered fractionation RT regimens; of the latter, both pure hyperfractination (HFX) and accelerated fractionation with concomitant boost (AFX CB) produced superior outcomes [21]. This RTOG trial produced important clinical evidence for the benefit of radiation dose intensification and shortening of the overall treatment time which had been demonstrated by other trial results and institutional experiences [2, 3, 21, 23, 24, 38, 40]. However, most approaches of dose intensification to the gross tumor volume (GTV) by three-dimensional conformal radiotherapy (3D-CRT) techniques require twice-daily irradiation. This has the disadvantages of reduced biological effectiveness of the cumulative nominal daily doses, and includes the need for repeated irradiation of normal and other target tissues overlying gross tumor.

Original languageEnglish (US)
Title of host publicationImage-Guided IMRT
PublisherSpringer Berlin Heidelberg
Pages301-317
Number of pages17
ISBN (Print)354020511X, 9783540205111
DOIs
StatePublished - 2006
Externally publishedYes

Fingerprint

Oropharynx
Mouth
Radiotherapy
Carcinoma
Conformal Radiotherapy
Salvage Therapy
Tumor Burden
Treatment Failure
Therapeutics
Survival Rate
Radiation
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Schmidt-Ullrich, R. K., Buck, D., Dogan, N., Siebers, J., Morris, M., & Wu, Y. (2006). IMRT for carcinomas of the oropharynx and oral cavity. In Image-Guided IMRT (pp. 301-317). Springer Berlin Heidelberg. https://doi.org/10.1007/3-540-30356-1_24

IMRT for carcinomas of the oropharynx and oral cavity. / Schmidt-Ullrich, Rupert K.; Buck, David; Dogan, Nesrin; Siebers, Jeffrey; Morris, Monica; Wu, Yan.

Image-Guided IMRT. Springer Berlin Heidelberg, 2006. p. 301-317.

Research output: Chapter in Book/Report/Conference proceedingChapter

Schmidt-Ullrich, RK, Buck, D, Dogan, N, Siebers, J, Morris, M & Wu, Y 2006, IMRT for carcinomas of the oropharynx and oral cavity. in Image-Guided IMRT. Springer Berlin Heidelberg, pp. 301-317. https://doi.org/10.1007/3-540-30356-1_24
Schmidt-Ullrich RK, Buck D, Dogan N, Siebers J, Morris M, Wu Y. IMRT for carcinomas of the oropharynx and oral cavity. In Image-Guided IMRT. Springer Berlin Heidelberg. 2006. p. 301-317 https://doi.org/10.1007/3-540-30356-1_24
Schmidt-Ullrich, Rupert K. ; Buck, David ; Dogan, Nesrin ; Siebers, Jeffrey ; Morris, Monica ; Wu, Yan. / IMRT for carcinomas of the oropharynx and oral cavity. Image-Guided IMRT. Springer Berlin Heidelberg, 2006. pp. 301-317
@inbook{348bba017ebf468f93ba3605e57071b0,
title = "IMRT for carcinomas of the oropharynx and oral cavity",
abstract = "Despite significant progress over the past decade, the loco-regional control and survival rates of 50-60{\%} for patients with locally-advanced oropharyngeal (OP) head and neck squamous cell carcinomas (HNSCC) with radiotherapy (RT) alone leave room for improvement [21] considering the limited options for salvage treatment after failure of the initial therapy. Current standards of RT have been re-defined by the RTOG- 9003 trial, comparing standard fractionation (SF) of 70 Gy, delivered in 35 fractions over 47 treatment days, with three different altered fractionation RT regimens; of the latter, both pure hyperfractination (HFX) and accelerated fractionation with concomitant boost (AFX CB) produced superior outcomes [21]. This RTOG trial produced important clinical evidence for the benefit of radiation dose intensification and shortening of the overall treatment time which had been demonstrated by other trial results and institutional experiences [2, 3, 21, 23, 24, 38, 40]. However, most approaches of dose intensification to the gross tumor volume (GTV) by three-dimensional conformal radiotherapy (3D-CRT) techniques require twice-daily irradiation. This has the disadvantages of reduced biological effectiveness of the cumulative nominal daily doses, and includes the need for repeated irradiation of normal and other target tissues overlying gross tumor.",
author = "Schmidt-Ullrich, {Rupert K.} and David Buck and Nesrin Dogan and Jeffrey Siebers and Monica Morris and Yan Wu",
year = "2006",
doi = "10.1007/3-540-30356-1_24",
language = "English (US)",
isbn = "354020511X",
pages = "301--317",
booktitle = "Image-Guided IMRT",
publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - IMRT for carcinomas of the oropharynx and oral cavity

AU - Schmidt-Ullrich, Rupert K.

AU - Buck, David

AU - Dogan, Nesrin

AU - Siebers, Jeffrey

AU - Morris, Monica

AU - Wu, Yan

PY - 2006

Y1 - 2006

N2 - Despite significant progress over the past decade, the loco-regional control and survival rates of 50-60% for patients with locally-advanced oropharyngeal (OP) head and neck squamous cell carcinomas (HNSCC) with radiotherapy (RT) alone leave room for improvement [21] considering the limited options for salvage treatment after failure of the initial therapy. Current standards of RT have been re-defined by the RTOG- 9003 trial, comparing standard fractionation (SF) of 70 Gy, delivered in 35 fractions over 47 treatment days, with three different altered fractionation RT regimens; of the latter, both pure hyperfractination (HFX) and accelerated fractionation with concomitant boost (AFX CB) produced superior outcomes [21]. This RTOG trial produced important clinical evidence for the benefit of radiation dose intensification and shortening of the overall treatment time which had been demonstrated by other trial results and institutional experiences [2, 3, 21, 23, 24, 38, 40]. However, most approaches of dose intensification to the gross tumor volume (GTV) by three-dimensional conformal radiotherapy (3D-CRT) techniques require twice-daily irradiation. This has the disadvantages of reduced biological effectiveness of the cumulative nominal daily doses, and includes the need for repeated irradiation of normal and other target tissues overlying gross tumor.

AB - Despite significant progress over the past decade, the loco-regional control and survival rates of 50-60% for patients with locally-advanced oropharyngeal (OP) head and neck squamous cell carcinomas (HNSCC) with radiotherapy (RT) alone leave room for improvement [21] considering the limited options for salvage treatment after failure of the initial therapy. Current standards of RT have been re-defined by the RTOG- 9003 trial, comparing standard fractionation (SF) of 70 Gy, delivered in 35 fractions over 47 treatment days, with three different altered fractionation RT regimens; of the latter, both pure hyperfractination (HFX) and accelerated fractionation with concomitant boost (AFX CB) produced superior outcomes [21]. This RTOG trial produced important clinical evidence for the benefit of radiation dose intensification and shortening of the overall treatment time which had been demonstrated by other trial results and institutional experiences [2, 3, 21, 23, 24, 38, 40]. However, most approaches of dose intensification to the gross tumor volume (GTV) by three-dimensional conformal radiotherapy (3D-CRT) techniques require twice-daily irradiation. This has the disadvantages of reduced biological effectiveness of the cumulative nominal daily doses, and includes the need for repeated irradiation of normal and other target tissues overlying gross tumor.

UR - http://www.scopus.com/inward/record.url?scp=84892230818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892230818&partnerID=8YFLogxK

U2 - 10.1007/3-540-30356-1_24

DO - 10.1007/3-540-30356-1_24

M3 - Chapter

AN - SCOPUS:84892230818

SN - 354020511X

SN - 9783540205111

SP - 301

EP - 317

BT - Image-Guided IMRT

PB - Springer Berlin Heidelberg

ER -